Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CETP | P11597 | 9/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13697601 | 0.89 | CETP (0.59) | GAACETPPTGDR2 | |
| SCHEMBL13697647 | 0.82 | GAA (0.50) | GAACETPPTGDR2KDM4ECYP3A4 | |
| SCHEMBL3557843 | 0.77 | CETP (0.50) | CETPGPBAR1KDM4E | |
| SCHEMBL3551798 | 0.76 | CETP (0.49) | CETPGPBAR1PTGDR2 | |
| SCHEMBL4184149 | 0.76 | CETP (0.44) | GAACETP | |
| SCHEMBL20768062 | 0.75 | CETP (0.41) | CETPGPBAR1 | |
| SCHEMBL20768063 | 0.74 | CETP (0.42) | CETPGPBAR1 | |
| SCHEMBL5669323 | 0.73 | CETP (0.50) | CETPGPBAR1LMNA | |
| SCHEMBL4847533 | 0.73 | CETP (0.46) | CETPGPBAR1PTGDR2 | |
| SCHEMBL17255700 | 0.71 | GAA (0.61) | GAAKDM4ECYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239865-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239865-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | APOB, LDLR, CETP | GAA 1959/4885CETP 3/4885GPBAR1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.